Vista Point Bio
Partnering with biotech leaders and investors to translate bold science into focused strategy, disciplined execution, and clear narratives that drive alignment and unlock value.
About
Vista Point Bio is a strategic advisory firm that partners with R&D leaders, founders, and investors to bring clarity to complex programs and platforms — from discovery through IND and beyond.At key inflection points — advancing a novel therapy, evaluating an asset, or preparing for investor engagement — we partner to sharpen strategy, pressure-test plans, and develop a focused, differentiated narrative.
What we do
R&D and Translational Strategy
• Design phase-appropriate development strategies aligned with the target product profile and disease context
• Bridge target biology with disease context, patient segmentation, indication strategy, and therapeutic rationalePortfolio and Pipeline Strategy
• Prioritize pipeline investments based on biological rationale, differentiation, and value inflection
• Identify new therapeutic opportunities for novel platform technologies
• Navigate trade-offs across stage, risk, and strategic optionality to guide portfolio decisionsScientific & Investor Narratives
• Craft compelling strategic narratives that resonate with strategic partners and investors to enable BD, M&A, and fundraising initiatives
• Distill complex science into clear, differentiated messagingOpportunity Assessment & Diligence
• Evaluate mechanistic rationale, preclinical evidence, and development feasibility to inform investment decisions
• Uncover key value drivers, risks, and whitespace opportunities
Founder
Dr. Matt Killeen is a biotech executive with nearly 20 years of experience at the intersection of science and strategy.Matt has founded and led a new therapeutic area at a global biotech, built and expanded pipelines, advanced genetic medicines towards the clinic, helped build and launch a precision medicine company, and served as CSO of a publicly traded biotech. Along the way, he's played a key role in driving and closing multiple BD and M&A transactions.He holds a PhD in cardiac electrophysiology from the University of Cambridge and held research fellowships at Massachusetts General Hospital and Harvard Medical School. He has also completed executive education at Oxford’s Saïd Business School and Stanford’s Innovation and Entrepreneurship Program.He holds fellowships from the Royal Society of Biology, the American College of Cardiology, and the Heart Rhythm Society, with therapeutic expertise spanning cardiovascular, rare / genetic diseases, CNS, and metabolic disorders, paired with broad modality experience including small molecules, biologics, and genetic medicines.
Get in touch
Vista Point Bio brings clarity, rigor, and strategic focus to advance innovative platforms and breakthrough programsEmail: [email protected]
Vista Point Bio is the strategic advisory arm of Vista Point Therapeutic Innovations LLC. © 2025 Vista Point Therapeutic Innovations LLC. All rights reserved.